- January 24, 2025
- Acadia Story
The J.P. Morgan Healthcare Conference is a cornerstone event in our industry. As the largest and most influential gathering of healthcare leaders and innovators, it serves as a platform to discuss the challenges and opportunities shaping our field.
This year’s 43rd Annual conference was no exception. It was an honor to represent Acadia Pharmaceuticals at this pivotal event and to share our forward-looking vision with the broader healthcare community. As CEO of Acadia Pharmaceuticals, I’ve seen how diverse experiences—from learning new skills to engaging with unique patient communities—help us approach challenges with fresh perspectives. These moments shape our ability to address unmet medical needs in neuroscience and rare diseases.
We stand on the cusp of a transformative moment in our company’s journey. Fueled by our innovative science, diverse expertise, and financial strength, we are poised for historic growth and an expanded impact on the lives of patients and their families.
A Milestone Year
In 2025, we anticipate reaching an extraordinary milestone: surpassing $1 billion in annual net sales. This achievement reflects the strength of our commercial franchises and our ability to deliver both for patients and for our shareholders. Our success is built on two foundational pillars: our neuropsychiatry and neuro-rare disease franchises. These pillars include first and only FDA-approved therapies for conditions that have long gone under-recognized and undertreated, underscoring our commitment to addressing critical unmet needs.
Expanding Our Impact
At Acadia, our mission is clear: to bring transformative therapies to patients in need and to raise awareness about the complexities of conditions often misunderstood by society.
For individuals impacted by Parkinson’s disease-related hallucinations and delusions, we are leveraging real-world evidence and employing cutting-edge AI technologies to enhance our reach and impact. Similarly, for those living with Rett syndrome, we are seeing strong persistence rates for our approved therapy in the U.S. and are actively working to expand our reach globally, including through the submission of a Marketing Authorization Application in Europe.
Through educational initiatives, such as Rett Revealed and More to Parkinson’s, we aim to empower patients, families, and caregivers with the tools and knowledge they need to navigate their journeys. By raising awareness and providing resources, we are fostering understanding and support for individuals living with central nervous system (CNS) and rare disorders.
Driving Innovation
Innovation is central to our mission of addressing the unmet medical needs of those living with CNS disorders and rare diseases. From advancing programs for Prader-Willi syndrome to exploring treatments for Alzheimer’s disease psychosis and Lewy body dementia, we are building a robust and high-impact pipeline of therapies.
Our recent acquisition of a program focused on essential tremor exemplifies our strategic approach to expanding our capabilities. Essential tremor, a condition marked by involuntary shaking, represents another opportunity for us to make a meaningful difference in patients’ lives.
Building a Strong Foundation
Our financial strength is the backbone of our ability to innovate and grow. It enables us to reinvest in our commercial franchises, expand our pipeline, and increase our field force, ensuring that we can reach more healthcare providers and patients. Meeting with caregivers and hearing their stories about the difference our therapies make for their loved ones fuels our purpose and urgency.
This mission is deeply personal for me. Both my parents have Alzheimer’s disease, and my mother experiences psychosis as part of her condition. While there are moments of levity, navigating the devastating effects of this disease underscores for me the critical importance of what we do at Acadia. We are not just advancing science; we are striving to bring hope and support to those living with complex and often misunderstood conditions.
Redefining What's Possible
Our collective experiences, shared commitment, and relentless pursuit of innovation drive everything we do at Acadia. Together, we are redefining what’s possible in neuroscience and rare diseases. The progress we have made is a testament to the dedication of our team, our partners, and the broader healthcare community.
I am immensely proud of what we have achieved and energized by the opportunities that lie ahead. Thank you to everyone who contributes to our mission. I look forward to all that lies ahead as we continue to make a meaningful difference for patients and their families.
Author
Catherine Owen Adams,
Chief Executive Officer
